Coskun 2022 — Retatrutide Discovery to Clinical PoC

Cell Metabolism·August 19, 2022

Tamer Coskun, Shweta Urva, William C. Roell, Hongchang Qu, et al.

Summary

Discovery paper describing the GLP-1/GIP/glucagon triple receptor agonist retatrutide and early clinical proof-of-concept data.

Study Details

Study Design

Discovery and preclinical/clinical proof-of-concept

Indication

Obesity and metabolic disease

Intervention

Retatrutide (LY3437943)

Risk of Bias Assessment

Eli Lilly internal research